Analysis of 13 Cases of Trichophyton tonsurans at a Clinic in Kumamoto Prefecture

Kunitake, Yuko; Noguchi, Hideko; Hiruma, Masataro

doi:10.2336/nishinihonhifu.72.136

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three cases received topical antifungal therapy for 2 weeks and were determined to be completely cured 4 weeks later (one case was treated with terbinafine 1% cream 157 and two cases were treated with luliconazole 1% cream) 158,159 . Two cases received topical therapy for 3 weeks (ketoconazole 2% cream 160 and terbinafine 1% cream), 161 six cases received treatment for 1 month (one case was treated with oxiconazole 1% cream, 162 one case was treated with terbinafine 1% cream, 163 three were cases treated with butenafine 1% cream, 159,164 and one case was treated with luliconazole 1% cream), 165 one case was treated for 6 weeks (butenafine 1% cream), 164 two cases were treated for 8 weeks (lanoconazole 1% cream), 166 and one case was treated for 13 weeks (lanoconazole 1% cream) 166 . The cases were determined to be cured at the end of topical cream use.…”

Section: Cq12: Is a Topical Antifungal Agent Recommended For T Tonsumentioning

confidence: 99%

Guidelines for the management of dermatomycosis (2019)

Mochizuki

Tsuboi

Iozumi

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

The "Guidelines for the management of dermatomycosis" of the Japanese Dermatological Association were first published in Japanese in 2009 and the Guidelines Committee of the Japanese Dermatological Association revised it in 2019. The first guidelines was prepared according to the opinions of the Guidelines Committee members and it was of educational value. The revised version is composed of introductory descriptions of the disease concepts, diagnosis, medical mycology and recent advances in treatment, along with clinical questions (CQ), which is intended to help in general practice for dermatologists. The CQ are limited to those involved in therapy but include some of the recently launched antifungal agents. The level of evidence and the degree of recommendation for each item were reviewed by the committee based on clinical studies published by 2018. For rare dermatomycoses, recommendations by the committee are described in the guidelines. In this field, there are still few good quality studies on treatment. Periodic revision in line with new evidence is necessary.

show abstract

Section: Cq12: Is a Topical Antifungal Agent Recommended For T Tonsumentioning

confidence: 99%